Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies

Paul E. Oran, Jason W. Jarvis, Chad Borges, Nisha D. Sherma, Randall W. Nelson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: The purpose of the work presented herein was to develop a high-throughput assay for the quantification of human insulin in plasma samples while simultaneously detecting, with high mass accuracy, any additional variant forms of insulin that might be present in each sample. Experimental design: A mass spectrometric immunoassay (MSIA) was designed in which anti-human insulin antibodies were immobilized to commercially available mass spectrometric immunoassay pipette tips and used to capture insulin and related protein variants from human plasma. Results: Standard curves for insulin exhibited linearity (average R 2 for three days of analysis=0.99) and assay concentration limits of detection and limits of quantification for insulin were found to be 1 and 15pM, respectively. Estimated coefficient of variations for inter-day experiments (n=3 days) were <8%. Simultaneously, the assay was shown to detect and identify insulin metabolites and synthetic insulin analogs (e.g. Lantus). Notably, insulin variants not known to exist in plasma were detected in diabetics. Conclusions and clinical relevance: This introductory study sets a foundation toward the screening of large populations to investigate insulin isoforms, isoform frequencies, and their quantification.

Original languageEnglish (US)
Pages (from-to)454-459
Number of pages6
JournalProteomics - Clinical Applications
Volume5
Issue number7-8
DOIs
StatePublished - Aug 2011

Fingerprint

Immunoassay
Proteomics
Insulin
Population
Assays
Protein Isoforms
Plasma (human)
Insulin Antibodies
Plasmas
Metabolites
Design of experiments
Limit of Detection
Screening
Research Design
Throughput

Keywords

  • Insulin
  • Microheterogeneity
  • Population proteomics

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. / Oran, Paul E.; Jarvis, Jason W.; Borges, Chad; Sherma, Nisha D.; Nelson, Randall W.

In: Proteomics - Clinical Applications, Vol. 5, No. 7-8, 08.2011, p. 454-459.

Research output: Contribution to journalArticle

Oran, Paul E. ; Jarvis, Jason W. ; Borges, Chad ; Sherma, Nisha D. ; Nelson, Randall W. / Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. In: Proteomics - Clinical Applications. 2011 ; Vol. 5, No. 7-8. pp. 454-459.
@article{2053d8f3d5cc40ab9cf6c93ea16017b4,
title = "Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies",
abstract = "Purpose: The purpose of the work presented herein was to develop a high-throughput assay for the quantification of human insulin in plasma samples while simultaneously detecting, with high mass accuracy, any additional variant forms of insulin that might be present in each sample. Experimental design: A mass spectrometric immunoassay (MSIA) was designed in which anti-human insulin antibodies were immobilized to commercially available mass spectrometric immunoassay pipette tips and used to capture insulin and related protein variants from human plasma. Results: Standard curves for insulin exhibited linearity (average R 2 for three days of analysis=0.99) and assay concentration limits of detection and limits of quantification for insulin were found to be 1 and 15pM, respectively. Estimated coefficient of variations for inter-day experiments (n=3 days) were <8{\%}. Simultaneously, the assay was shown to detect and identify insulin metabolites and synthetic insulin analogs (e.g. Lantus). Notably, insulin variants not known to exist in plasma were detected in diabetics. Conclusions and clinical relevance: This introductory study sets a foundation toward the screening of large populations to investigate insulin isoforms, isoform frequencies, and their quantification.",
keywords = "Insulin, Microheterogeneity, Population proteomics",
author = "Oran, {Paul E.} and Jarvis, {Jason W.} and Chad Borges and Sherma, {Nisha D.} and Nelson, {Randall W.}",
year = "2011",
month = "8",
doi = "10.1002/prca.201000112",
language = "English (US)",
volume = "5",
pages = "454--459",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "7-8",

}

TY - JOUR

T1 - Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies

AU - Oran, Paul E.

AU - Jarvis, Jason W.

AU - Borges, Chad

AU - Sherma, Nisha D.

AU - Nelson, Randall W.

PY - 2011/8

Y1 - 2011/8

N2 - Purpose: The purpose of the work presented herein was to develop a high-throughput assay for the quantification of human insulin in plasma samples while simultaneously detecting, with high mass accuracy, any additional variant forms of insulin that might be present in each sample. Experimental design: A mass spectrometric immunoassay (MSIA) was designed in which anti-human insulin antibodies were immobilized to commercially available mass spectrometric immunoassay pipette tips and used to capture insulin and related protein variants from human plasma. Results: Standard curves for insulin exhibited linearity (average R 2 for three days of analysis=0.99) and assay concentration limits of detection and limits of quantification for insulin were found to be 1 and 15pM, respectively. Estimated coefficient of variations for inter-day experiments (n=3 days) were <8%. Simultaneously, the assay was shown to detect and identify insulin metabolites and synthetic insulin analogs (e.g. Lantus). Notably, insulin variants not known to exist in plasma were detected in diabetics. Conclusions and clinical relevance: This introductory study sets a foundation toward the screening of large populations to investigate insulin isoforms, isoform frequencies, and their quantification.

AB - Purpose: The purpose of the work presented herein was to develop a high-throughput assay for the quantification of human insulin in plasma samples while simultaneously detecting, with high mass accuracy, any additional variant forms of insulin that might be present in each sample. Experimental design: A mass spectrometric immunoassay (MSIA) was designed in which anti-human insulin antibodies were immobilized to commercially available mass spectrometric immunoassay pipette tips and used to capture insulin and related protein variants from human plasma. Results: Standard curves for insulin exhibited linearity (average R 2 for three days of analysis=0.99) and assay concentration limits of detection and limits of quantification for insulin were found to be 1 and 15pM, respectively. Estimated coefficient of variations for inter-day experiments (n=3 days) were <8%. Simultaneously, the assay was shown to detect and identify insulin metabolites and synthetic insulin analogs (e.g. Lantus). Notably, insulin variants not known to exist in plasma were detected in diabetics. Conclusions and clinical relevance: This introductory study sets a foundation toward the screening of large populations to investigate insulin isoforms, isoform frequencies, and their quantification.

KW - Insulin

KW - Microheterogeneity

KW - Population proteomics

UR - http://www.scopus.com/inward/record.url?scp=79960887190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960887190&partnerID=8YFLogxK

U2 - 10.1002/prca.201000112

DO - 10.1002/prca.201000112

M3 - Article

VL - 5

SP - 454

EP - 459

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 7-8

ER -